Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Genentech, Inc. Drug Patent Portfolio

Genentech, Inc.'s Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Genentech, Inc.:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Genentech, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Genentech, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma Genentech, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC Genentech, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer Genentech, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib Genentech, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of RO7890597 in Healthy Adult Volunteers Genentech, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies Genentech, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer Genentech, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Genentech, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) Genentech, Inc. NA WITHDRAWN
(Aug 1, 2026)
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer Genentech, Inc. NA TERMINATED
(Aug 1, 2026)
PHASE1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis Genentech, Inc. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) Genentech, Inc. NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 Genentech, Inc. NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma Genentech, Inc. NA COMPLETED
(Apr 1, 2026)
PHASE2
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Genentech, Inc. NA COMPLETED
(Apr 1, 2026)
PHASE2


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List